N-ratio: A novel independent prognostic factor for patients with stage-III cutaneous melanoma

Annals of Surgical Oncology

Volumn 15, Issue 1, 2008, Pages 310-315

  Rossi, Carlo Riccardo ^a   Mocellin, Simone ^a   Pasquali, Sandro ^a   Pilati, Pierluigi ^a   Nitti, Donato ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Cutaneous melanoma; Lymph node metastasis; N ratio; Prognostic factors

Indexed keywords

ADULT; AGE DISTRIBUTION; ARTICLE; CANCER STAGING; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MELANOMA; PREDICTION; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SEX RATIO; SURVIVAL RATE; TUMOR VOLUME;

FEMALE; HUMANS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 38049175043     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-007-9641-z     Document Type: Article

References (21)

1. Balch CM, Buzaid AC, Soong SJ, et al. Final version of the American Joint Committee on Cancer Staging System for Cutaneous Melanoma. J Clin Oncol 2001; 16:3635-48
2. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors Analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer Melanoma Staging System. J Clin Oncol 2001; 16:3622-34
3. Balch CM, Soong SJ, Atkins MB, et al. An evidence staging system for cutaneous melanoma. CA Cancer J Clin 2004; 54:131-49
4. Thompson JF, Scolyer RA, Kefford RF. Cutaneous melanoma. Lancet 2005; 365:687-701
5. Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med 2004; 351:998-1012
6. Verna S, Quirt I, McrCeady D, Bak K, Charette M, Iscoe N. Systematic review of systematic adjuvant therapy for patients at high risk of recurrent melanoma. Cancer 2006; 106:1431-2
7. Kirkwood JM, Manola J, Ibrahim J, Sondak V, Ernstoff MS, Rao U. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 2004; 10:1670-7
8. Lens MB, Dawes M. Interferon alfa therapy for malignant melanoma: a systemic review of randomized controlled trials. J Clin Oncol 2002; 20:1818-25
9. Wheatley K, Natalie I, Hancock B, Gore M, Eggermont Alexander, Suciu S. Does adjuvant interferon-α for high-risk melanoma provide worthwhile benefit? A meta-analysis of the randomized trials. Cancer Treat Rev 2003; 29:241-52
10. Gogas H, Ioannovich J, Dafni U, et al. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med 2006; 354:709-718
11. Nitti D, Marchet A, Olivieri M, et al. Ratio between metastatic and examined lymph nodes is an independent prognostic factor after D2 resection for gastric cancer: analysis of a large European monoinstitutional experience. Ann Surg Oncol 2003; 10:1077-85
12. Marchet A, Mocellin S, Ambrosi A, et al. The ratio between metastatic and examined nodes (N ratio) is an independent prognostic factor in gastric cancer regardless the type of lymphadenectomy. Results from an Italian multicentric study in 1853 patients. Ann Surg 2007; 245:543-52
13. Woodward WA, Vinh-Hung V, Ueno NT, et al. Prognostic value of nodal ratios in node-positive breast cancer. J Clin Oncol 2006; 24:2910-6
14. Kuru B. Prognostic significance of total number of nodes removed, and ratio of positive nodes to removed nodes in positive breast carcinoma. Eur J Surg Oncol 2006; 32:1082-8
15. Berger AC, Watson JC, Ross EA, Hoffman JP. The metastatic/examined lymph node ratio is an important prognostic factor after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am Surg 2004; 70:235-40
16. Lehmann EL, Romano JP. Testing statistical hypotheses, Third Edition. Springer-Verlag, New York, 2005
17. Mocellin S, Provenzano M, Rossi CR, Pilati PL, Nitti D, Lise M. DNA Array-based gene profiling. From surgical specimen to the molecular portrait of cancer. Ann Surg 2005; 241:16-26
18. Bittner M, Meltzer P, Chen Y, et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 2000; 406:536-40
19. Lewis TB, Robinson JE, Bastien R. Molecular classification of melanoma using real-time quantitative reverse transcription-polymerase chain reaction. Cancer 2005; 104:1678-86
20. Cheon AD, Essner R, Wanek LA, Morton DL. Judging the therapeutic value of lymph node dissections for melanoma. J Am Coll Surg 2000; 191:16-23
21. Galliot-Repkat C, Cailliod R, Trost O, et al. The prognostic impact of the extent of lymph node dissection in patients with stage III melanoma. Eur J Surg Oncol 2006; 32:790-4